International Consensus Classification News Today

Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

It can also help identify patients who would benefit from disease-specific therapies.

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

The model may help clinicians identify patients who would benefit from disease-specific therapies or enrollment into clinical trials.

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

During an OncLive® workshop titled Key Updates in the Management of Acute Myeloid Leukemia and Their Application in Clinical Practice, moderated by Naval Daver, MD, faculty reviewed updates to the classification of acute myeloid leukemia and its effects on the treatment paradigm and provided insight on the management of adverse-risk and secondary acute myeloid leukemia.